In particular, in non-small cell lung cancer (NSCLC), driven by activating epidermal growth factor receptor (EGFR) mutations, EGFR-TKIs have emerged as the optimal therapeutic approach [20]. Here, EGFR is linked to non-small cell lung carcinoma.